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related to obesity (15, 16) . However, the effects of weight loss on myocardial FA oxidation, MVO 2 , and efficiency are unknown. Furthermore, it is not known whether weight loss-induced changes in myocardial metabolism predict improvement in cardiac function in humans. We hypothesized (i) weight loss would reverse the high rates of MVO 2 and FA metabolism and decrease the cardiac inefficiency associated with obesity, (ii) improvements in MVO 2 and/or FA metabolism would predict improved LV relaxation. To evaluate the relationship between metabolism and functional changes over a wide range of weight loss, two different modes of weight loss were studied, diet and gastric bypass surgery. Positron emission tomography (PET) was used to quantify MVO 2 and myocardial FA metabolism. Echocardiography with tissue Doppler imaging was used to quantify cardiac structure, systolic and diastolic function (LV relaxation (E′) and E/E′).
Methods and Procedures study subjects
Obese (BMI >30 kg/m 2 ) subjects enrolled in this prospective, interventional study. Surgery subjects were recruited from the bariatric surgery center at Barnes-Jewish Hospital, diet subjects from the Volunteer for Health office. All subjects completed screening, including a history, physical examination, and blood testing. Individuals with suggestive histories were screened for coronary disease and sleep apnea using exercise stress echocardiography and polysomnography. Subjects were sedentary upon study entry. Exclusion criteria: weight >159 kg, age <21 or >50 years (to decrease the impact of aging) (17) , insulin-requiring diabetes, heart failure, a history of coronary disease, chest pain, or untreated sleep apnea, being an active smoker, pregnant, lactating, or postmenopausal. Subjects in the surgery group and the diet groups were purposefully studied after different periods of weight loss (16 ± 5 and 8 ± 2 months, respectively) in order to maximize weight loss and weight stability (14, 18) , and minimize weight regain and subject drop out (14) . This study was designed to recruit subjects who would undergo different weight loss interventions in order to obtain a large spectrum of weight loss, and hence, metabolic and functional changes for comparison. Both groups were screened and imaged over the same 5-year time frame by the same research team, using the same equipment. Written, informed consent was obtained before subject participation.
Gastric bypass surgery
The same surgeon (J.C.E.) performed all bypass procedures at BarnesJewish Hospital using standard surgical techniques. Briefly, a small (~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb constructed by transecting the jejunum distal to the ligament of Treitz and creating a jejunojejunostomy 75 cm distal to the transection. diet Diet subjects participated in 20 group behavior modification sessions, led by a behaviorist, a registered dietitian, and a physical therapist. The meal plans ranged from 1,200 to 1,500 kcal/day, depending on subject sex and BMI. The plans were designed to achieve a ≤1% body weight/ week. Macronutrient content of the plan followed the Expert Panel's recommendations on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults, convened by the NIH and the Dietary Guidelines for Americans (19) . Subjects completed daily food records. Subjects were taught a variety of weight-management skills. The exercise approach included a balance of strength, flexibility, balance, and endurance instruction. Goals gradually increased to 30 min of exercise, 5 days/week. Two weeks before follow-up imaging studies, calorie intake was adjusted to maintain stable body weight.
cardiac Pet imaging and image analysis
The evening before the imaging study, at a standardized time, all subjects were given a standard meal containing 12 kcal/kg adjusted body weight (=ideal body weight + ((actual body weight-ideal body weight) × 0.25)). After this, subjects remained fasted until their imaging studies were completed. All imaging started at 8 am.
Imaging studies were performed with a Siemens tomograph (ECAT 962 HR+; Siemens Medical Systems, Iselin, NJ). Subjects underwent positioning and transmission scans. Myocardial blood flow (needed for myocardial FA metabolism calculation), MVO 2 , and FA utilization, oxidation, and esterification were obtained using PET imaging after injections of 15 O-water, 1-11 C-acetate, and 1-11 C-palmitate, using wellvalidated kinetic models as previously described (4, 17, (20) (21) (22) . The calculations that describe the relationship between the different measures of FA metabolism are: FA utilization/g = blood flow/g × FA uptake/g × (average plasma-free FA at the time of the 1-11 C-palmitate injection); FA utilization/g = FA oxidation/g + esterification/g. The intraclass correlation coefficient for the MVO 2 image analysis is 0.96. Total MVO 2 , FA utilization, and oxidation were calculated by multiplying each by LV mass. One subject did not undergo FA imaging due to technical difficulties.
Measurement of plasma insulin and substrates
Subjects underwent phlebotomy throughout the PET study. Samples were drawn before the study and after each tracer injection during the imaging that followed. Plasma insulin and substrate levels presented here are averages of those measurements. Plasma insulin levels were measured by radioimmunoassay, glucose by automated hexokinase assay. Plasma-free FA was measured using an enzymatic method (NEFA C kit, WAKO Chemicals USA, Richmond, VA). The homeostasis model assessment of insulin resistance was used to calculate insulin resistance, using the first AM, fasting glucose and insulin levels (23) .
echocardiography
Immediately following MVO 2 measurement, all subjects underwent a complete two-dimensional, M-mode, and Doppler echocardiographic study using second harmonic imaging. Two-dimensional guided M-mode measurements were obtained from the parasternal cross-sectional view for LV diameter and wall thickness measurements. Ejection fraction was calculated using the modified Simpson method. LV end-diastolic and left atrial volumes were measured using the method of discs. Left atrial volumes were indexed to body surface area. LV mass was measured using the area-length method. LV mass was also indexed to height 2.7 . Pulsed-wave Doppler-derived transmitral inflow measurements were obtained from the apical fourchamber view with the sampling gate at the mitral leaflet tips. The early diastolic (E) and late atrial (A) velocities were measured and the E/A ratio, a load-dependent measure of diastolic function was calculated. The relatively load-independent tissue Doppler-derived measures of LV systolic function and relaxation, S′ and E′, respectively, were measured at the septal and lateral annulus and averaged to obtain one S′ and one E′ for each echocardiogram (24) . E/E′ (septal) ratio was also obtained (25) . LV mass, E′, and E/E′ were not obtained on one, one, and five subjects, respectively. Calculations: cardiac output = time velocity integral of the LV outflow tract x its area; cardiac work = cardiac output × mean arterial pressure; efficiency = work/ MVO 2 (work and MVO 2 were converted to joules/g/min as previously described) (26, 27) . A single investigator (A.D.W.) blinded to all clinical parameters, measured all echocardiograms. The intraobserver correlation coefficient was obtained to assess reproducibility of measurements by remeasuring 50% of the studies in a random fashion. All reported measurements represent the average of three consecutive cardiac cycles. Reproducibility measurements (intraobserver correlation coefficient and (95% confidence intervals)) for the primary outcomes of LV diastolic function and LV mass were as follows: E-wave (0.987 (0.968-0.995)), E′ (0.919 (0.726-0.952)), and LV mass (0.856 (0.620-0.929)).
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statistical analyses
All data are expressed as mean ± s.d. SAS software (version 9.2; SAS Institute, Cary, NC) was used. Between-group comparisons used unpaired Student's t-tests. Within-group comparisons used paired Student's t-tests. Fisher's exact tests were used to compare proportions between groups. Linear regression was used to evaluate the relations between continuous variables. All cardiac endpoints and independent variables were predetermined. The tissue Doppler measure of LV relaxation (E′) was the primary measure of LV relaxation because of its loadindependence. A priori it was decided to use the continuous variables mean arterial pressure and homeostasis model assessment of insulin resistance were used rather than categorical variables hypertension, diabetes, or metabolic syndrome status. If more than one variable correlated with an endpoint, analysis of covariance was used to determine its independent predictor(s). To enter the multivariate analyses, an independent variable had to have a P < 0.10 in the univariate analyses. In the multivariate models, each independent variable was adjusted for all other independent variables. A P < 0.05 was considered significant.
results subject characteristics
There were few differences between groups at baseline ( Tables 1 and 2 ). Most importantly, the groups' BMI, plasma triglycerides, LV mass, hemodynamics, homeostasis model assessment of insulin resistance, and systolic function were similar. The only significant baseline differences between the group were that the surgery group was slightly older and had a higher fraction of women, diabetic (3/10), hypertensive (5/10), and treated sleep apnea (3/10) subjects than the diet group; LV end-diastolic volume was lower in the surgery group, likely because there was a higher percentage of women in this group, and women are known to have smaller LV cavity size than men.
After weight loss, the only medication change made was the two subjects in the surgery group taking oral diabetic medications discontinued their use. Tables 1 and 2 also show weight loss-induced changes. The surgery group had a greater decrease in BMI than the diet group (P < 0.0001). Surgery decreased plasma triglycerides and insulin resistance. Three subjects were diabetic pre-but not postsurgery. The diet group's insulin resistance also decreased. Heart rate decreased in the diet group.
Weight loss effects on MVo 2 and lV efficiency MVO 2 . Baseline total MVO 2 or MVO 2 indexed to heart weight did not differ between groups. After weight loss total MVO 2 decreased in both groups (Figure 1 ). In the surgery group, this was mostly due to the decrease in LV mass because MVO 2 /g did not change. In the diet group, this was mostly due to decreased MVO 2 /g (P = 0.009) because LV mass did not change. Total MVO 2 change correlated strongly with the decrease in BMI (Figure 1c and Table 3 ). Change in MVO 2 /g trended toward a correlation with a change in cardiac work (P = 0.10).
Efficiency. Baseline myocardial efficiency (work/MVO 2 ) was similar between groups and did not change in either group after intervention despite decreases in MVO 2 , likely due to a trend toward a decreased cardiac work in the surgery subjects (P = 0.10).
Weight loss effects on myocardial Fa metabolism and its components
Plasma substrates and hormones. Baseline plasma-free FAs (Table 4 ) and insulin were similar between groups (data not shown). Plasma glucose was different between the surgery and the diet groups (6.4 ± 1.8 vs. 5.0 ± 0.6 μmol/ml, P = 0.004). Postsurgery, glucose decreased to 4.9 ± 0.4 μmol/ ml (P = 0.02); insulin decreased from 16.2 ± 10.3 to 4.2 ± 2.5 μU/ml (P = 0.004). Insulin decreased in the diet group (13.9 ± 5.9 to 10.6 ± 6.8 μU/ml, P = 0.009). 
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Myocardial blood flow. Baseline myocardial blood flow (ml/g/ min) was higher in the surgery than the diet group and did not change in either ( Table 4) .
Myocardial FA metabolism. Baseline myocardial FA metabolism measures/g were similar between groups and did not change with weight loss (Table 4) . However, myocardial FA oxidation/g change correlated with MVO 2 /g change (r = 0.39, P = 0.04). Baseline total myocardial FA utilization and oxidation were similar between groups. After surgery, total myocardial FA utilization decreased, mirroring the postsurgical LV mass decrease, and total myocardial FA oxidation trended lower (Figure 2a,b) . Total and per gram FA esterification did not change with either intervention (Table 4) . Total FA utilization change trended toward relating to BMI change ( Table 3) . No FA metabolism measure correlated with diastolic function change ( Table 5) .
Weight loss effects on diastolic function and relation to myocardial metabolism LV relaxation. Baseline E′ was worse in the surgery group than in the diet group, but LV relaxation improved markedly after surgery ( Table 2 and Figure 3a,b) . Improved relaxation correlated with weight loss amount, increased insulin sensitivity, an LV mass decrease, and a total MVO 2 decrease ( Table 5 and Figure 3c) . In multivariate modeling, in all subjects, total MVO 2 predicted LV relaxation improvement independent of BMI change ( Table 6 ). LV mass decrease also independently predicted LV relaxation improvement. However, because of sex-related differences in MVO 2 and LV mass (26, 27) we repeated the multivariate analysis in only the women, and decreased MVO 2 was the sole independent predictor of LV relaxation. In this model, BMI change and total MVO 2 change accounted for 55% of the improvement in LV relaxation. The multivariate analysis was not repeated in the men given their limited numbers.
E/E′. Baseline E/E′ was worse in the surgery group than in the diet group but improved (decreased) after surgery (Tables 1 and 2) . The improvement correlated robustly with weight loss amount ( Table 3) , insulin resistance improvement (Table 3) , total MVO 2 decrease (r = 0.54, P = 0.005), LV mass decrease (r = 0.73, P < 0.0001), and end-diastolic volume change (r = 0.54, P = 0.005). Weight loss independently predicted E/E′ improvement.
Weight loss effects on lV remodeling
Notwithstanding the constancy in blood pressure before and after weight loss in both groups, LV mass decreased after surgery ( Table 2) . Weight loss amount correlated with decreased LV mass ( Table 3) . LV end-diastolic volume also decreased significantly after weight loss, which together with the aforementioned decrease in E/E′ suggests a decrease in preload and/ or plasma volume.
dIscussIon
The present study is the first to demonstrate, in men and women, that weight loss can ameliorate both the myocardial oxygen and FA oxidation derangements related to obesity and that the change in MVO 2 predicts improved LV relaxation. Even moderate, diet-induced weight loss decreased MVO 2 (total and per gram) whereas marked weight loss decreased total MVO 2 . The decrease in total MVO 2 related to decreased BMI. Marked weight loss decreased total FA utilization, and 
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total FA oxidation trended lower. LV relaxation and E/E′ (an estimate of LV filling pressure) (25) , both improved after surgery-induced weight loss. In all subjects, LV relaxation improvement correlated with amount of weight loss, LV mass change, insulin resistance improvement, and a decrease in total MVO 2 . In multivariate analyses, total MVO 2 decrease independently predicted improved LV relaxation in all subjects and alone in women.
The first novel finding of this study is that weight loss decreased MVO 2 requirements. This is similar to the finding that whole body oxygen consumption decreases with weight loss (28) . In our study, myocardial FA oxidation/g decreases contributed to MVO 2 /g change, which is in agreement with studies showing that FAs are the major substrate oxidized in the postabsorptive heart (4), and that FAs "cost" relatively more oxygen to burn than glucose (29) . There is also a suggestion that part, but not all, of the decrease in MVO 2 /g is due to a decrease in work (P = 0.10), consistent with the fact that MVO 2 is used for both mechanical and nonmechanical processes. The absence of LV mass change in the presence of this MVO 2 /g change after diet therapy suggests that metabolism changes may precede, and thus contribute to significant structural and functional remodeling, consistent with a study in animals demonstrating that metabolism changes precede trophic changes (30) . The present study's finding that total MVO 2 changes postsurgery (after an LV mass change, i.e., remodeling) and those of previous studies also demonstrate that the converse is true: that LV structural remodeling influences metabolism (31) . The lack of a significant change in MVO 2 /g in the surgery group may result from smaller numbers of surgery subjects, or it may be that there is a continuum of metabolic and structural changes that are not perfectly matched as weight loss progresses. E.g., MVO 2 /g may change first, then after significant structural remodeling occurs and the denominator decreases, the ratio becomes similar to baseline but total MVO 2 is decreased. A study with multiple 
sampling points is needed to prove this; however, subject radiation exposure and costs currently limit many repeated samplings using PET.
Another major finding of this study was the strong correlation between change in MVO 2 and improvement in LV relaxation, independent of weight loss amount or blood pressure or myocardial FA metabolism change. The relaxation improvement after surgery (28%) is greater than that in surgical weight loss studies with shorter-term follow-up (~18% after 3 months) (12, 32) . Although it may appear counterintuitive that a decrease in MVO 2 could increase in LV relaxation, there are possible mechanisms for this salutary link. First, MVO 2 as measured in our study by C-11 acetate injection and PET imaging is almost exclusively from the function of mitochondria, a known source of free radical generation (33) , which contributes to cardiac dysfunction development in animal models of obesity (6, 7) . Thus, it is logical to propose that the decrease in MVO 2 found in the current study in humans may relate to decreased reactive oxygen species generation and hence, functional improvement (see proposed working model, Figure 4) . Second, decreased MVO 2 may improve LV relaxation if there is better coupling of MVO 2 to ATP generation, and of ATP generation to relaxation. I.e., if less energy generated from oxidative metabolism is dissipated (by uncoupling protein and/or adenine nucleotide transporter activity) and/or if less oxygen use is "wasted" (33) by the creation of free radicals, more ATP should be available for relaxation. This is supported by a study in adipose tissue, which showed that uncoupling proteins 2 and 3 mRNA expression decreases after weight loss (34) . With this improved coupling, we had expected efficiency would improve. However, the lack of a change in efficiency (cardiac minute work/MVO 2 ) may be due to the fact that this common measure of cardiac work used does not directly incorporate the work of LV sarcomeric relaxation (moving actin and myosin apart), an ATP-requiring process (as evidenced by rigor mortis rather than relaxation when metabolism stops) (35) .
We also hypothesized that myocardial FA metabolism would decrease with weight loss and that this would also relate to improved LV diastolic function. We did find a decrease in total myocardial FA utilization and a trend toward a decrease in total FA oxidation but no difference in FA utilization or oxidation/g. This is partially consistent with the findings of 
Viljanen et al., who found a decrease in myocardial FA uptake (µmol/100 g/min) after diet therapy (15) . Differences in tracers, the sex of the study subjects, and types of weight loss may account for the differences in our results. For example, the study by Viljanen et al. was in men (15) , and the present study included both men and women. Sex has a major affect on myocardial metabolism at baseline (26, 27) , and it may also affect myocardial responses to weight loss. The present study was not powered to evaluate the effects of sex on the heart's metabolic response to weight loss and requires future study. The diet study by Viljanen et al. also had a marked weight loss within a much shorter period of time, and it may be that there is a continuum of myocardial FA metabolic responses depending on rapidity of weight loss and whether there is a weight stabilization period or not (15) . Our study further showed that decreased myocardial FA oxidation contributes to an overall decrease in MVO 2 thereby potentially indirectly contributing to an improvement in relaxation. Our finding that LV relaxation abnormalities are reversible in obese humans, suggests that at this stage of obesity-related heart disease, mechanisms besides or in addition to FA-induced apoptosis likely contribute to diastolic dysfunction.
limitations
Although this study does show the strength of the relationships between myocardial FA metabolism and MVO 2 and relaxation, it does not prove cause and effect, direction of the association, or the potential influence of unmeasured factors. More studies are needed to further test the proposed working model shown in Figure 4 . Given the short-term risk of mortality and insurance issues with surgery, subjects were not randomized to treatment, and so the groups were heterogeneous. Despite this, the groups were similar in many respects. In the surgery arm, only white women enrolled because they represent ~80% of surgery patients, similar to other studies (36) . The surgery group was slightly older at baseline than the diet 
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group, however, a significant aging effect would be expected to decrease FA metabolism, which was not seen (17) . The size of the groups were relatively small, which increases the possibility of a type 2 error in the analyses that did not show a difference from pre-to postintervention e.g., the surgery group's size may have contributed to the lack of a significant change in MVO 2 /g; however, the primary focus of this study was to evaluate the effects of a spectrum of weight loss on heart metabolism, structure, and function rather than to compare the effect of different methods. Measurement of local, cardiac reactive oxygen species and changes in myocardial metabolism of other substrates and energetics was not done.
clinical implications
Our data support an association between excessive MVO 2 and diastolic dysfunction in humans, suggesting that altering MVO 2 might be a target for new therapies aimed at improving diastolic dysfunction. Our results also demonstrate that patients with significant diastolic function who lose marked amounts of weight can have dramatic improvements in diastolic dysfunction. Thus, patients with obesity-related LV hypertrophy, decreased LV relaxation, and/or estimated increased filling pressures may reap the most cardiac benefits from surgery surgery-induced weight loss. Whether these particular changes result in a long-term decrease in cardiovascular morbidity and mortality deserves further study. Because FA oxidation is a major contributor to overall mitochondrial oxygen consumption, total myocardial oxygen consumption (MVO 2 ) then decreases. Total MVO 2 may also decrease as a result of decreased uncoupling protein (UCP) or adenine nucleotide transporter (ANT) activity. A decrease in total MVO 2 should lead to improved left ventricular (LV) relaxation (an ATP-requiring process), if there is improved flow of energy directed toward ATP production and subsequent LV relaxation rather than dissipation by UCP or ANT. A decrease in MVO 2 may also lead to diminished free radical production and consequent oxidative stress (Ox. Stress), which can negatively affect relaxation. Text with an asterisk (*) indicates findings of this study.
